Global transport and logistics service provider GEODIS has officially secured the International Air Transport Association (IATA) Center of Excellence for Independent Validators (CEIV) Pharma certification for its strategic site in Hyderabad. The international accreditation certifies that the facility’s temperature-controlled infrastructure, quality management systems, operational procedures, and field personnel comply fully with rigorous global standards for handling sensitive biopharmaceuticals and medical supplies.
The achievement marks the expansion of GEODIS’ certified cold-chain footprint within India, positioning the forwarder to capture higher volumes of time- and temperature-critical healthcare exports originating from one of the world’s primary life sciences manufacturing clusters.
Validating Cold-Chain Compliance and Risk Management
To attain the CEIV Pharma standard, GEODIS’ Hyderabad operations underwent an exhaustive independent audit covering every phase of its warehouse handling and transit management loops. The validation confirms that the facility effectively mitigates the environmental and operational risks associated with specialized healthcare logistics through several audited capabilities:
- Stringent Temperature Integrity: Demonstrating precise climate control to prevent product degradation during temporary storage and runway staging windows.
- Proactive Risk Mitigation: Applying advanced hazard analysis protocols to anticipate and bypass potential supply chain disruptions, such as terminal delays or extreme ambient heat.
- Continuous Personnel Training: Ensuring all ground handling teams are certified in current Good Distribution Practices (GDP) and proper cold-chain emergency procedures.
- Advanced Shipment Visibility: Utilizing end-to-end telemetry and monitoring systems to track internal container climates and cargo security in real time.
Anchoring Global Supply Chains in India’s Premier Bio-Hub
The choice of Hyderabad as a certified node is a strategic response to the shifting concentration of global pharmaceutical manufacturing. The city functions as a major capital for global generic drug production, vaccine development, and biotechnological research, exporting massive volumes of finished medical products daily to highly regulated markets across Europe, North America, and the Asia-Pacific region.
With the addition of Hyderabad, GEODIS expands its global network of CEIV Pharma-certified installations to 29 sites worldwide. This includes nine highly coordinated facilities distributed across the Asia-Pacific and Middle East regions, establishing a verifiably compliant, resilient corridor that guarantees product safety from the manufacturing plant gates to the destination airport tarmac.
Chris Cahill, Managing Director for the Middle East and India Sub-continent at GEODIS, noted that Hyderabad is one of the world’s most important pharmaceutical manufacturing and export hubs, making it a critical addition to the company’s healthcare logistics network. He stated that the certification enhances GEODIS’ ability to support customers moving increasingly complex, temperature-sensitive products through global markets. He added that the investment reflects the company’s expanding commitment to India, where a workforce of over 1,000 employees across 15 locations serves a broad customer base, reinforcing the resilience and consistency of GEODIS’ global healthcare offering.
อัพเดตข่าวสารและบทความที่น่าสนใจในอุตสาหกรรมโลจิสติกส์ก่อนใคร ผ่าน Line Official Account @Airfreight Logistics เพียงเพิ่มเราเป็นเพื่อน @Airfreight Logistics หรือคลิกที่นี่
